United Therapeutics Corporation Intangible Assets, Net (Including Goodwill)
United Therapeutics Corporation (UTHR) had Intangible Assets, Net (Including Goodwill) of $114.10 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Goodwill and Other
us-gaap:IntangibleAssetsNetIncludingGoodwill · last filed 2026-08-05
- 2026-06-30: Intangible Assets, Net (Including Goodwill) $114.10M.
- 2026-03-31: Intangible Assets, Net (Including Goodwill) $115.50M.
- 2025-12-31: Intangible Assets, Net (Including Goodwill) $116.50M.
- 2025-09-30: Intangible Assets, Net (Including Goodwill) $116.70M.
| Period end | Intangible Assets, Net (Including Goodwill) | Intangible Assets, Net (Including Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $114.10M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $115.50M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $116.50M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $116.70M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $111.50M 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $111.70M 10-Q · filed 2025-04-30 | |
| 2024-12-31 | $111.90M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $112.10M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $115.20M 10-Q · filed 2024-07-31 | |
| 2024-03-31 | $115.40M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $114.20M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $44.40M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $44.50M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $44.50M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $44.50M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $44.50M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $44.60M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $44.60M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $44.60M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $44.70M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $44.70M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $44.70M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $158.10M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $158.20M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $158.20M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $158.30M 10-Q · filed 2020-04-29 | |
| 2019-12-31 | $158.30M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $158.40M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $161.90M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $170.80M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $170.80M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $167.70M 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $45.60M 10-Q · filed 2018-08-01 | |
| 2018-03-31 | $45.60M 10-Q · filed 2018-05-02 | |
| 2017-12-31 | $45.60M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $45.70M 10-Q · filed 2017-10-25 | |
| 2017-06-30 | $45.80M 10-Q · filed 2017-07-27 | |
| 2017-03-31 | $33.60M 10-Q · filed 2017-04-26 | |
| 2016-12-31 | $33.80M 10-K · filed 2018-02-21 | |
| 2016-09-30 | $34.00M 10-Q · filed 2016-10-27 | |
| 2016-06-30 | $34.10M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $34.30M 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $28.40M 10-K · filed 2017-02-22 | $28.38M 10-K · filed 2016-02-25 |
| 2015-09-30 | $28.53M 10-Q · filed 2015-10-27 | |
| 2015-06-30 | $28.80M 10-Q · filed 2015-07-28 | |
| 2015-03-31 | $29.14M 10-Q · filed 2015-04-28 | |
| 2014-12-31 | $29.46M 10-K · filed 2016-02-25 | |
| 2014-09-30 | $14.50M 10-Q · filed 2014-10-28 | |
| 2014-06-30 | $15.34M 10-Q · filed 2014-07-29 | |
| 2014-03-31 | $13.74M 10-Q · filed 2014-04-29 | |
| 2013-12-31 | $14.12M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $14.61M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $14.94M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $15.66M 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $16.41M 10-K · filed 2014-02-25 | |
| 2012-09-30 | $16.66M 10-Q · filed 2012-11-01 | |
| 2011-12-31 | $22.09M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |